• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 24, 2017

View Archived Issues

LEAPs in bounds: Nabriva lefamulin not a 'lung' shot thanks to specificity: CMO

Pharma giant Glaxosmithkline plc (GSK) made "lemonade with lemons" using its pleuromutilin platform, Nabriva AG's chief medical officer (CMO), Elyse Seltzer, told BioWorld Today, but her company seems on the way to something sweeter with lefamulin, an antibiotic from the class due to report phase III LEAP1 data later this year in community-acquired bacterial pneumonia (CABP). Read More

Xbiotech's Xilonix fails to convince CHMP, as 11 other drugs make the grade

DUBLIN – Shares in Xbiotech Inc. (NASDAQ:XBIT) fell by 41 percent Friday on news that its European application for its advanced colorectal cancer therapy Xilonix (MABp1), was likely to fail.  Read More

Bench Press: BioWorld looks at translational medicine

Methods to manipulate gene expression in Bacteroides, the most common type of bacterium in the gut microbiome of Western populations, have been developed and reported by two separate research groups. Read More

Abbvie HCV data suggest new ENDUR-ing combo cure for GT3 patients

AMSTERDAM – A combination of two Abbvie Inc. drugs, glecaprevir and pibrentasvir (G/P, previously ABT-493/ABT-530), helped 95 percent of noncirrhotic patients infected with the world's most common genotype of chronic hepatitis C virus (HCV) achieve undetectable levels of the virus in their blood at 12 weeks (SVR12), according to new data from the study, ENDURANCE-3, presented Saturday at the International Liver Congress. Read More

Aiming to eliminate hepatitis, WHO chronicles a daunting scourge

AMSTERDAM – The World Health Organization's (WHO) first global report on hepatitis estimates 325 million people worldwide are living with chronic hepatitis B or C virus (HBV or HCV) infections, with the vast majority lacking access to life-saving testing and treatment. The situation has left millions of people at risk of a slow progression to chronic liver disease, cancer and death, it said. Read More

Astellas: More bolt-on deals expected as the patent cliff draws near

HONG KONG – Having recently completed the acquisition of Belgium-based Ogeda SA, Astellas Pharma Inc. now has a potentially key drug candidate at its disposal as well as access to new programs to its drug development pipeline, all of which could provide boosts to its bottom line as it deals with an imminent patent cliff. (See BioWorld Today, April 4, 2017.) Read More

Sanofi's dengue vaccine cleared for conditional 2-year trial In Malaysia

HONG KONG – Sanofi Pasteur Ltd.'s dengue vaccine has been granted a conditional registration for two years in Malaysia while phase IV studies are carried out. Read More

Financings

Apricus Biosciences Inc., of San Diego, priced an underwritten public offering of 5.03 million units, each consisting of one common share and one warrant to purchase 0.75 of a common share, at $1.40 per unit. Read More

Other news to note

Valeant Pharmaceuticals International Inc., of Laval, Quebec, said following the evaluation and approval of its patient access and pricing committee, the firm decided to list Siliq (brodalumab) injection at $3,500 per month. Read More

Appointments and advancements

Marinus Pharmaceuticals Inc., of Radnor, Pa., named Lorianne K. Masuoka chief medical officer. Read More

In the clinic

Aurinia Pharmaceuticals Inc., of Victoria, British Columbia, disclosed additional 48-week results from its global phase IIb AURA-LV (AURA) study in lupus nephritis during the National Kidney Foundation Spring Clinical Meetings in Orlando, Fla. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 24, 2025.
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    Otsuka licenses Harbour’s bispecific T-cell engager for $670M

    BioWorld
    Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd....
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe